Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
1.036 JPY | +1,47 % | -4,60 % | -17,25 % |
Resumen de negocios
Número de empleados: 1 793
Ventas por actividad
JPY en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Reagent
84,4
%
| 54 605 | 80,7 % | 65 925 | 84,4 % | +20,73 % |
Brokerage
10,5
%
| 11 426 | 16,9 % | 8 200 | 10,5 % | -28,23 % |
Genetic Medicine
3,4
%
| 148 | 0,2 % | 2 640 | 3,4 % | +1.683,78 % |
Equipment
1,8
%
| 1 518 | 2,2 % | 1 375 | 1,8 % | -9,42 % |
Ventas por región
JPY en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Japan
58,4
%
| 34 076 | 50,3 % | 45 667 | 58,4 % | +34,02 % |
United States
16,5
%
| 10 186 | 15,0 % | 12 886 | 16,5 % | +26,51 % |
China
13,8
%
| 11 908 | 17,6 % | 10 799 | 13,8 % | -9,31 % |
Europe
6,3
%
| 4 668 | 6,9 % | 4 949 | 6,3 % | +6,02 % |
Asia excluding Japan and China
4,5
%
| 6 614 | 9,8 % | 3 546 | 4,5 % | -46,39 % |
Others
0,4
%
| 244 | 0,4 % | 293 | 0,4 % | +20,08 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Director of Finance/CFO | 68 | 01/06/14 | |
Koichi Nakao
PSD | President | 61 | 01/04/02 |
Takuya Kakemi
ADM | Chief Administrative Officer | - | - |
Junichi Mineno
COO | Chief Operating Officer | 63 | 01/04/04 |
Director/Board Member | 60 | 01/01/09 | |
Masanobu Kimura
BRD | Director/Board Member | 60 | 01/05/13 |
Human Resources Officer | - | - | |
Akihiko Kita
AUD | Comptroller/Controller/Auditor | 64 | 01/04/05 |
Corporate Officer/Principal | - | - | |
Masahide Tamaki
AUD | Comptroller/Controller/Auditor | 64 | 01/04/05 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Hisashi Omiya
CHM | Chairman | 80 | 01/04/02 |
Masanobu Kimura
BRD | Director/Board Member | 60 | 01/05/13 |
Koichi Nakao
PSD | President | 61 | 01/04/02 |
Director of Finance/CFO | 68 | 01/06/14 | |
Director/Board Member | 60 | 01/01/09 | |
Junichi Mineno
COO | Chief Operating Officer | 63 | 01/04/04 |
Kazuko Kimura
BRD | Director/Board Member | 73 | 01/06/19 |
Nobuko Kawashima
BRD | Director/Board Member | 61 | 01/06/16 |
Director/Board Member | 52 | 01/06/20 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 0 | 120 415 600 | 47 065 600 ( 39,09 %) | 0 | 39,09 % |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Cellectis AB
Cellectis AB BiotechnologyHealth Technology Part of Takara Holdings, Inc., Cellectis AB is a Swedish company that manufactures and distributes stem cell-related products. The company is based in Gothenburg, Sweden. Cellectis was acquired by Takara Bio, Inc. from Cellectis SA on September 04, 2014. |
Biotechnology
|
Takara Bio Europe SAS
Takara Bio Europe SAS Medical SpecialtiesHealth Technology Takara BIO Europe SAS provides kits, reagents, instruments, and services that enable life sciences researchers to achieve their experimental objectives. It offers automation systems, stem cell research, real time PCR, nucleic acid purification, cloning, cell biology assays, gene function, antibodies, and ELISAs. The company is headquartered in Saint-Germain-en-Laye, France. |
Medical Specialties
|
Sector
Ventas por actividad
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
-17,25 % | 783 M | |
+67,53 % | 63,85 mil M | |
-0,77 % | 41,83 mil M | |
+44,98 % | 40,65 mil M | |
-10,87 % | 27,12 mil M | |
+13,30 % | 26,52 mil M | |
-22,79 % | 18,69 mil M | |
+4,70 % | 12,73 mil M | |
+24,10 % | 12,11 mil M | |
+27,41 % | 12,07 mil M |
- Bolsa de valores
- Acciones
- Acción 4974
- Empresa Takara Bio Inc.